144 related articles for article (PubMed ID: 8754757)
1. Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists.
Van Tine BA; Azizeh BY; Trivedi D; Phelps JR; Houslay MD; Johnson DG; Hruby VJ
Endocrinology; 1996 Aug; 137(8):3316-22. PubMed ID: 8754757
[TBL] [Abstract][Full Text] [Related]
2. Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors.
Azizeh BY; Van Tine BA; Trivedi D; Hruby VJ
Peptides; 1997; 18(5):633-41. PubMed ID: 9213355
[TBL] [Abstract][Full Text] [Related]
3. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
[TBL] [Abstract][Full Text] [Related]
4. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
[TBL] [Abstract][Full Text] [Related]
5. Synthetic linear and cyclic glucagon antagonists.
Dharanipragada R; Trivedi D; Bannister A; Siegel M; Tourwe D; Mollova N; Schram K; Hruby VJ
Int J Pept Protein Res; 1993 Jul; 42(1):68-77. PubMed ID: 8396562
[TBL] [Abstract][Full Text] [Related]
6. Synthetic glucagon antagonists and partial agonists.
Zechel C; Trivedi D; Hruby VJ
Int J Pept Protein Res; 1991 Aug; 38(2):131-8. PubMed ID: 1664420
[TBL] [Abstract][Full Text] [Related]
7. Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
Ransjö M; Fredholm BB; Lerner UH
Bone Miner; 1988 Jan; 3(3):225-34. PubMed ID: 2462948
[TBL] [Abstract][Full Text] [Related]
8. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
Kumari M; Cover PO; Poyser RH; Buckingham JC
Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
[TBL] [Abstract][Full Text] [Related]
10. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist.
Unson CG; Gurzenda EM; Merrifield RB
Peptides; 1989; 10(6):1171-7. PubMed ID: 2560175
[TBL] [Abstract][Full Text] [Related]
11. Effects of the cyclic nucleotide phosphodiesterase inhibitors, rolipram, 3-isobutyl-1-methylxanthine, amrinone and zaprinast, on pancreatic exocrine secretion in dogs.
Iwatsuki K; Horiuchi A; Ren LM; Chiba S
Eur J Pharmacol; 1991 Dec; 209(1-2):63-8. PubMed ID: 1726088
[TBL] [Abstract][Full Text] [Related]
12. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of two glucagon antagonists: receptor binding, adenylate cyclase, and effects on blood plasma glucose levels.
Gysin B; Johnson DG; Trivedi D; Hruby VJ
J Med Chem; 1987 Aug; 30(8):1409-15. PubMed ID: 3039134
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells.
Morgan AJ; Murray KJ; Challiss RA
Biochem Pharmacol; 1993 Jun; 45(12):2373-80. PubMed ID: 7687130
[TBL] [Abstract][Full Text] [Related]
16. Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.
Wachtel H
J Neural Transm; 1983; 56(2-3):139-52. PubMed ID: 6190991
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation.
Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS
Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940
[TBL] [Abstract][Full Text] [Related]
20. Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values.
Murphy GJ; Houslay MD
Biochem J; 1988 Jan; 249(2):543-7. PubMed ID: 2449179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
